IDEXX Laboratories Inc. (IDXX)
IDEXX Laboratories Statistics
Share Statistics
IDEXX Laboratories has 81.04M shares outstanding. The number of shares has increased by -1.87% in one year.
| Shares Outstanding | 81.04M |
| Shares Change (YoY) | -1.87% |
| Shares Change (QoQ) | -1.03% |
| Owned by Institutions (%) | 87.26% |
| Shares Floating | 80.2M |
| Failed to Deliver (FTD) Shares | 69 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.83M, so 3.49% of the outstanding shares have been sold short.
| Short Interest | 2.83M |
| Short % of Shares Out | 3.49% |
| Short % of Float | 4.56% |
| Short Ratio (days to cover) | 4.27 |
Valuation Ratios
The PE ratio is 38.4 and the forward PE ratio is 30.34. IDEXX Laboratories's PEG ratio is 6.51.
| PE Ratio | 38.4 |
| Forward PE | 30.34 |
| PS Ratio | 8.75 |
| Forward PS | 6.4 |
| PB Ratio | 21.37 |
| P/FCF Ratio | 42.72 |
| PEG Ratio | 6.51 |
Enterprise Valuation
IDEXX Laboratories has an Enterprise Value (EV) of 34.79B.
| EV / Sales | 8.93 |
| EV / EBITDA | 27.38 |
| EV / EBIT | 37.45 |
| EV / FCF | 43.6 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.31 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 0.78 |
| Debt / FCF | 1.24 |
| Interest Coverage | 36.16 |
Financial Efficiency
Return on Equity is 55.65% and Return on Invested Capital is 33.87%.
| Return on Equity | 55.65% |
| Return on Assets | 26.96% |
| Return on Invested Capital | 33.87% |
| Revenue Per Employee | $354.32K |
| Profits Per Employee | $80.72K |
| Employee Count | 11,000 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 3.98 |
Taxes
| Income Tax | 221.96M |
| Effective Tax Rate | 20% |
Stock Price Statistics
The stock price has increased by -13.84% in the last 52 weeks. The beta is 1.5, so IDEXX Laboratories's price volatility has been higher than the market average.
| Beta | 1.5 |
| 52-Week Price Change | -13.84% |
| 50-Day Moving Average | 427.06 |
| 200-Day Moving Average | 449.61 |
| Relative Strength Index (RSI) | 50.94 |
| Average Volume (20 Days) | 851.01K |
Income Statement
In the last 12 months, IDEXX Laboratories had revenue of 3.9B and earned 887.87M in profits. Earnings per share was 10.77.
| Revenue | 3.9B |
| Gross Profit | 2.38B |
| Operating Income | 1.13B |
| Net Income | 887.87M |
| EBITDA | 1.27B |
| EBIT | 1.14B |
| Earnings Per Share (EPS) | 10.77 |
Balance Sheet
The company has 288.27M in cash and 986.95M in debt, giving a net cash position of -698.68M.
| Cash & Cash Equivalents | 288.27M |
| Total Debt | 986.95M |
| Net Cash | -698.68M |
| Retained Earnings | 5.33B |
| Total Assets | 3.29B |
| Working Capital | 331.98M |
Cash Flow
In the last 12 months, operating cash flow was 929M and capital expenditures -130.92M, giving a free cash flow of 798.08M.
| Operating Cash Flow | 929M |
| Capital Expenditures | -130.92M |
| Free Cash Flow | 798.08M |
| FCF Per Share | 9.68 |
Margins
Gross margin is 61.04%, with operating and profit margins of 28.95% and 22.78%.
| Gross Margin | 61.04% |
| Operating Margin | 28.95% |
| Pretax Margin | 28.48% |
| Profit Margin | 22.78% |
| EBITDA Margin | 32.61% |
| EBIT Margin | 28.95% |
| FCF Margin | 20.48% |
Dividends & Yields
IDXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.6% |
| FCF Yield | 2.34% |
Analyst Forecast
The average price target for IDXX is $535, which is 30% higher than the current price. The consensus rating is "Buy".
| Price Target | $535 |
| Price Target Difference | 30% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Jun 16, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jun 16, 2015 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 16.17 |
| Piotroski F-Score | 7 |